Sunday, 17 December 2017

Teva Pharmaceutical to Cut 14,000 Jobs globally

The number of Jobs to be cut in India are unknown. However, the number of job cuts globally are 25 %. Teva Pharmaceutical Industries Ltd. has presence in India and has manufacturing plants at following locations:
1.     Plot No. A-2, A-2/1, A-2/2 UPSIDC Industrial Area, Bijnor Road, Gajraula, Amroha 244235, India (IND).
2.     Plot No. Q1 to Q4 Industrial Area Ghirongi, Malanpur, Distt. Bhind (M.P.) 477117, India (IND).
3.     C/O Ticel Biopark Limited, Chennai, Tamilnadu 600113, India (IND). Through Actavis.
4.     Plot No N-15 MIDC, Additional Ambernath, Thane, Maharashtra 421506, India (IND). Through Watson.
 Following news story from Wall Street Journal provides the details of the global story.
Teva Pharmaceutical Industries Ltd. is cutting more than 25% of its workforce, or about 14,000 employees around the world, closing factories and research centers and suspending its dividend—the Israeli firm’s most recent move to cut costs and pare debt.

Teva, the world’s biggest seller of generic drugs, didn’t detail where it is cutting jobs. At the end of the third quarter, it employed about 53,000, most of them in Europe and the U.S.

Teva has been hit hard by declining generics prices in the U.S. and increased competition for its blockbuster multiple-sclerosis drug. It also recently emerged from a period of boardroom and executive-suite turmoil. Directors had clashed on the firm’s strategy after swallowing a big acquisition that saddled it with heavy debt.​

Earlier this year, the firm shuffled board members and appointed Kare Schultz as chief executive—after the top job sat vacant for nine months.

Mr. Schultz, who took over in September, has tried to move quickly to restore stability. Teva said the two-year restructuring plan will cut $3 billion in costs by the end of 2019, out of an estimated cost base of $16.1 billion in 2017. Teva will also record a one-off charge of at least $700 million in 2018, mainly related to severance costs.

Making workforce reductions of this magnitude is difficult,” Mr. Schultz wrote in a memo to employees. “However, there is no alternative to these drastic steps in the current situation.”

Investors have called for months for sweeping changes to Teva’s sprawling operations and what critics have called an unwieldy supply chain, to better cope with the turbulent U.S. generics market. One in seven prescriptions in the U.S. is a Teva drug.

It is also facing new competition to its biggest patented drug, while investors have grown concerned about the $35 billion in debt it took on last year when then-Chief Executive Erez Vigodman bought Allergan PLC’s generics unit.

The threat of job cuts has faced opposition in Israel, where lawmakers already have called on the government to withdraw tax benefits for Teva. The country’s largest labor union said it will strike over the job losses announced Thursday. Teva is cutting 1,700 jobs in Israel. As of the end of last year, it employed a bit over 6,800 there.

Teva also said it wouldn’t pay an annual bonus this year and will review the potential for additional divestment of noncore assets.
Mr. Schultz has shuffled the company’s leadership ranks and said he would combine its generic and specialty businesses to cut costs. The firm also said research and development operations for the two businesses would be combined.

Mr. Schultz took charge of the Israeli firm only days before it announced disappointing third-quarter results and cut its earnings-per-share estimate for the year. The third-quarter results followed a $6.1 billion write-down in August, blamed on its U.S. generics unit. That dragged the company’s quarterly net loss to $6.04 billion. Its shares lost a quarter of their market value that day.

Teva also this year has said it would face competition for its blockbuster specialty drug Copaxone earlier than planned. The drug makes up roughly 20% of the firm’s total revenue.

Announcing the first batch of Drug discovery course

Pharma Literati Centre of Excellence in Pharma Education is pleased to announce the launch of "Certificate Course in Drug Discovery and Bulk Drugs (Active Pharmaceutical Ingredient)". 

The course is being delivered by Dr. Praful Gupta, who is is working as Senior Manager with E. Z. Bioxcel Gurugram (Gurgaon) in the Department of Drug Discovery. Dr. Gupta is an experienced medicinal chemist with a rich experience of more than 15 years in drug discovery (Ranbaxy and Daiichi Sankyo). His area of expertise includes Inflammation, Infection, Small molecule kinase inhibitor and Oncology and pre-clinical drug discovery. He did his Ph.D entitled Synthesis of Biologically active compound as 5HT1A receptor antagonists with Dr. Ian A. Cliffe at Ranbaxy Laboratory Limited. In 15 years of research experience, apart from publications and patents, Dr. Gupta got several opportunities to show cases his research work at various national and international meetings. 

Team Pharma Literati would like to thank Dr. Praful Gupta for his contribution.

Saturday, 16 December 2017

3rd GPAT Mock test conducted on 10th-15th December 2017_Results

The Pharmacad mock test series for GPAT continued with it's third test. 

The winners for the 3rd test eligible for the complimentary registrations for the courses of Pharma Literati Centre of Excellence in pharma education are

1. Hardik Joshi from Bombay College of Pharmacy who scored 229/ 500 marks.

2. Nachiket Dandekar from Bombay College of Pharmacy who scored 202/500 marks.

3. Suraj Gupta from K M Kundnani College of Pharmacy who scored 199/500 marks.

The registrations are open still and students can participate in the 4th test scheduled in the month of December 2017.

The application form for the registration is available at,

Tuesday, 12 December 2017

Last 3 days to register for Drug discovery course

Certificate Course in Drug Discovery and Bulk Drugs (Active Pharmaceutical Ingredient) is commencing on 15th December and the registrations are still open for the same.

The details are available at:

The students can also opt for payments in installments and we are also providing complimentary registrations for the chemistry faculty members.

Thursday, 7 December 2017

Internship opportunities at Pharma Literati

Pharma Literati is pleased to announce the internship opportunities for undergraduate/ post-graduate students in pharmacy/ life sciences domain. 

Looking for passionate, career-focused, highly motivated individuals who wish to join the dynamic team of Pharma Literati. 
  • Location: Work from home;
  • Tenure: 2-3 months;
  • Requirements: Internet connection and laptop/desktop at home;
  • Stipend: Depending upon the contribution of the intern;
  • Certificate: To be provided to the intern on successful completion of internship;
  • Send your CVs to

Work with us_Part time opportunities for Mumbai based students

Pharma Literati is pleased to announce the internship opportunities for undergraduate/ post-graduate students in pharmacy/ life sciences domain. 

Looking for passionate, career-focused, highly motivated individuals who wish to join the dynamic team of Pharma Literati. 

  • Profile: The students would work on a collaborative project along with an industry expert for the purpose of original research work or review or literature survey or market research; Also, the students would work as bloggers for this tenure. 
  • Location: Work from home;
  • Tenure: 2-3 months during summer vacation;
  • Joining date: Flexible, after the examinations;
  • Requirements: Internet connection and laptop/desktop at home;
  • Stipend: No stipend in the form of cash; However, expenses if any, during the internship would be reimbursed; Also, few opportunities available to get benefited via different platforms; 
  • Eligibility: B. Pharm/ M. Pharm students with basic understanding of internet and Microsoft Office;
  • Certificate: To be provided to the intern on successful completion of internship;
  • Project: The students can publish the work during the internship in co-authorship with their mentor who would be assigned to them during the internship. 

Send your CVs to before 31st December, 2017. Only 2-3 positions available. 

2nd Annual Pharma Literati Essay Contest

Pharma Literati is inviting students and faculties in the field of Pharmacy/Science/Biotechnology/ Life Sciences, all across to participate in the 2nd annual pharma literati essay contest. 

The essay contest is organized with an objective to provide a platform to students and faculties to explore new opportunities  in the field of life sciences.

PRIZES: With total prizes worth more than 50 thousand rupees. Certificate of participation for all the participants.

1st PRIZE worth: Rs 12000/-
2nd PRIZE worth: Rs 7000/-
3rd PRIZE worth: Rs 4000/-
One student from every institute in India would receive a prize worth Rs 1000/-

**Please note the prizes are not in the form of cash and cannot be reclaimed for cash component.

The selected essays would be published online on pharma literati.

TOPICS (Write on ANY ONE topic):
Need of skills development in pharmaceutical curriculum;
Indian Pharma Industry: Changing dynamics;
Entrepreneurship scenario after the pharmacy education

1. Graduates/ Post graduates/ PhD students from Pharmacy/ Science/ Biotechnology/ Life Sciences sector;
2. Faculty from Science/ Biotechnology/ Life Sciences domains;
3. Any industry professional from pharma/ bioscience or biotechnology sectors;

         Step 1: Subscribe to
   Step 2: Send us the entries for the essay as a word/PDF file by 31st January 2018    to or

ANNOUNCEMENT OF WINNERS: In the 2nd week of February 2018 via pharma literati blog.

To know more, please write to or

1. There is no restriction of page or word limit. The author/s are advised to explore their imagination to write and come up with the best suitable essay.
2. Any font type or size can be used. However, Arial 10 or Times New Roman 12 is recommended. 
3. Send the essay to by 31st January 2018 by email.
4. The authors are also required to follow the pharma literati blog by email. The link is available at the left-hand side of the blog page just below the feedcount. 
5. Co-authorship is also allowed upto three authors.
6. The prizes are not in the form of cash and cannot be reimbursed by cash. 

Tuesday, 5 December 2017

Walk-in interview at Cognizant Mumbai for Pharmacovigilance on 7 Dec 2017

Walk-in interview at Cognizant Mumbai for Pharmacovigilance on 7 Dec 2017 (Thursday) Education- only fresher B pharma /M pharma. (2015, 2016 & 2017) No experience required. Time of reporting: 9 am – 11:30 am Venue: Cognizant Technology Solutions 2nd floor, building no 9, mindspace SEZ, Thane- belapur road, opposite Airoli railway station, Airoli. Work Location: Mumbai Forward cv at Name- Girish Mali Emp ID - 631603 Contact number: 8208458193 Note - pan card , aadhar card and voter ID is compulsory.

***The information is available on social media. Pharma Literati has not confirmed the authenticity of the information. The readers are requested to confirm with the concerned person.

Monday, 4 December 2017

NAAC Accreditation results_27th November 2017_Pharmacy Colleges

On 27th November, NAAC published the results for the accreditation by the 29th Standing Committee. Following pharmacy institutions were accredited in the 1st Cycle. No pharmacy institute was accredited in the 2nd, 3rd or 4th cycle.

Nova College of Pharmaceutical Education and Research, Jupudi, Krishna, Vijayawada – 521456
Andhra Pradesh
Dadasaheb Balpande College of Pharmacy, Nagpur – 440037
Institute of Chemical Technology (Deemedto-be-University u/s 3 of the UGC Act 1956), Matunga, Mumbai – 400019

All our activities are helping many pharmaceutical institutions for the NBA or NAAC accreditation to seek the vital marks. We are already providing these services to various pharma educational institutions. To take these efforts to next level, we are launching the professional assistance for all the aspiring institutes. We are providing assistance to many institutions at minimum or zero cost depending upon the desired activities at institute level. We are just one email or call away.